These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 30635160)

  • 1. A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis.
    Jacobson MR; Watts JJ; Boileau I; Tong J; Mizrahi R
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):330-348. PubMed ID: 30635160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.
    Millán-Guerrero RO; Isais-Millán S
    Gac Med Mex; 2019; 155(5):471-474. PubMed ID: 32091020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenia.
    Leweke FM
    Curr Top Behav Neurosci; 2009; 1():387-96. PubMed ID: 21104393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune system: a possible nexus between cannabinoids and psychosis.
    Suárez-Pinilla P; López-Gil J; Crespo-Facorro B
    Brain Behav Immun; 2014 Aug; 40():269-82. PubMed ID: 24509089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Social Factors and Animal Models of Cannabis Use.
    Hood L
    Int Rev Neurobiol; 2018; 140():171-200. PubMed ID: 30193704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids and psychosis.
    D'Souza DC
    Int Rev Neurobiol; 2007; 78():289-326. PubMed ID: 17349865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cannabis and endocannabinoids in the genesis of schizophrenia.
    Fernandez-Espejo E; Viveros MP; Núñez L; Ellenbroek BA; Rodriguez de Fonseca F
    Psychopharmacology (Berl); 2009 Nov; 206(4):531-49. PubMed ID: 19629449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies.
    Sloan ME; Grant CW; Gowin JL; Ramchandani VA; Le Foll B
    Acta Pharmacol Sin; 2019 Mar; 40(3):342-350. PubMed ID: 30166624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuropharmacology of cannabinoid receptor ligands in central signaling pathways.
    Brunt TM; Bossong MG
    Eur J Neurosci; 2022 Feb; 55(4):909-921. PubMed ID: 32974975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoid system in psychotic and mood disorders, a review of human studies.
    Garani R; Watts JJ; Mizrahi R
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 106():110096. PubMed ID: 32898588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoids, cannabinoids and the regulation of anxiety.
    Petrie GN; Nastase AS; Aukema RJ; Hill MN
    Neuropharmacology; 2021 Sep; 195():108626. PubMed ID: 34116110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid system and multiple sclerosis.
    Baker D; Pryce G
    Curr Pharm Des; 2008; 14(23):2326-36. PubMed ID: 18781983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of the CB1 Receptor Ligands on the Schizophrenia-Like Effects in Mice Induced by MK-801.
    Kruk-Slomka M; Budzynska B; Slomka T; Banaszkiewicz I; Biala G
    Neurotox Res; 2016 Nov; 30(4):658-676. PubMed ID: 27577742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists.
    Gerra G; Zaimovic A; Gerra ML; Ciccocioppo R; Cippitelli A; Serpelloni G; Somaini L
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):46-52. PubMed ID: 19832688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions
.
    Spanagel R
    Dialogues Clin Neurosci; 2020 Sep; 22(3):241-250. PubMed ID: 33162767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events.
    Davidson C; Opacka-Juffry J; Arevalo-Martin A; Garcia-Ovejero D; Molina-Holgado E; Molina-Holgado F
    Adv Pharmacol; 2017; 80():135-168. PubMed ID: 28826533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia.
    Vigano D; Guidali C; Petrosino S; Realini N; Rubino T; Di Marzo V; Parolaro D
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):599-614. PubMed ID: 18789179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.